[1]
|
Ajani JA, D'Amico TA, Bentrem DJ, et al. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2022, 20: 167-192. doi: 10.6004/jnccn.2022.0008 |
[2]
|
International Agency for Research on Cancer. GLOBOCAN 2020: stomach cancer fact sheet[EB/OL]. (2020-12)[2022-05-01]. https://gco.iarc.fr/today/data/factsheets/cancers/7-Stomach-fact-sheet.pdf. |
[3]
|
Morgan E, Arnold M, Camargo MC, et al. The current and future incidence and mortality of gastric cancer in 185 countries, 2020-40: A population-based modelling study[J]. EClinicalMedicine, 2022, 47: 101404. doi: 10.1016/j.eclinm.2022.101404 |
[4]
|
Sitarz R, Skierucha M, Mielko J, et al. Gastric cancer: epidemiology, prevention, classification, and treatment[J]. Cancer Manag Res, 2018, 10: 239-248. doi: 10.2147/CMAR.S149619 |
[5]
|
Ma J, Shen H, Kapesa L, et al. Lauren classification and individualized chemotherapy in gastric cancer[J]. Oncol Lett, 2016, 11: 2959-2964. doi: 10.3892/ol.2016.4337 |
[6]
|
Hu B, El Hajj N, Sittler S, et al. Gastric cancer: classification, histology and application of molecular pathology[J]. J Gastrointest Oncol, 2012, 3: 251-261. |
[7]
|
Crew KD, Neugut AI. Epidemiology of gastric cancer[J]. World J Gastroenterol, 2006, 12: 354-362. doi: 10.3748/wjg.v12.i3.354 |
[8]
|
Amin MB, Edge SB, Greene FL, et al. AJCC Cancer Staging Manual[M]. 8th ed. New York: Springer, 2017. |
[9]
|
Sarela AI, Lefkowitz R, Brennan MF, et al. Selection of patients with gastric adenocarcinoma for laparoscopic staging[J]. Am J Surg, 2006, 191: 134-138. doi: 10.1016/j.amjsurg.2005.10.015 |
[10]
|
Abdalla EK, Pisters PWT. Staging and preoperative evaluation of upper gastrointestinal malignancies[J]. Semin Oncol, 2004, 31: 513-529. doi: 10.1053/j.seminoncol.2004.04.014 |
[11]
|
Mezhir JJ, Shah MA, Jacks LM, et al. Positive peritoneal cytology in patients with gastric cancer: natural history and outcome of 291 patients[J]. Ann Surg Oncol, 2010, 17: 3173-3180. doi: 10.1245/s10434-010-1183-0 |
[12]
|
Song L, Qian X, Xin D, et al. Efficacy and toxicity of neoadjuvant immune checkpoint inhibitors in resectable gastric cancer: A meta-analysis and systematic review[EB/OL]. [2022-05-01]. https://meetings.asco.org/abstracts-presentations/204818. |
[13]
|
Andre T, Tougeron D, Piessen G, et al. Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in patients (pts) with localized microsatellite instability-high (MSI)/mismatch repair deficient (dMMR) oeso-gastric adenocarcinoma (OGA): The GERCOR NEONIPIGA phase Ⅱ study[EB/OL]. [2022-05-01]. https://meetings.asco.org/abstracts-presentations/205214. |
[14]
|
Trabucco SE, Gowen K, Maund SL, et al. A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability and Pan-Tumor Characterization of 1000 Microsatellite Instability-High Cases in 67, 000 Patient Samples[J]. J Mol Diagn, 2019, 21: 1053-1066. doi: 10.1016/j.jmoldx.2019.06.011 |
[15]
|
Willis J, Lefterova MI, Artyomenko A, et al. Validation of microsatellite instability detection using a comprehensive plasma-based genotyping panel[J]. Clin Cancer Res, 2019, 25: 7035-7045. doi: 10.1158/1078-0432.CCR-19-1324 |
[16]
|
Kato S, Okamura R, Baumgartner JM, et al. Analysis of circulating tumor DNA and clinical correlates in patients with esophageal, gastroesophageal junction, and gastric adenocarcinoma[J]. Clin Cancer Res, 2018, 24: 6248-6256. doi: 10.1158/1078-0432.CCR-18-1128 |
[17]
|
Dikken JL, Jansen EP, Cats A, et al. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastic cancer[J]. J Clin Oncol, 2010, 28: 2430-2436. doi: 10.1200/JCO.2009.26.9654 |
[18]
|
Park SH, Sohn TS, Lee J, et al. Phase Ⅲ trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrence chemoradiotherapy in gastric cancer: final report of the Adjuvant Chemoradiotherapy In Stomach Tumors trial, including survival and subset analyses[J]. J Clin Oncol, 2015, 33: 3130-3136. doi: 10.1200/JCO.2014.58.3930 |
[19]
|
Lee J, Lim do H, Kim S, et al. Phase Ⅲ trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial[J]. J Clin Oncol, 2012, 30: 268-273. |
[20]
|
Park SH, Lim DH, Sohn TS, et al. A randomized phase Ⅲ trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiotion with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial[J]. Ann Oncol, 2021, 32: 368-374. doi: 10.1016/j.annonc.2020.11.017 |
[21]
|
Al-Batran SE, Pauligk C, Homann N, et al. The feasi-bility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+)[J]. Eur J Cancer, 2013, 49: 835-842. doi: 10.1016/j.ejca.2012.09.025 |
[22]
|
Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase Ⅲ study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group[J]. J Clin Oncol, 2006, 24: 4991-4997. doi: 10.1200/JCO.2006.06.8429 |
[23]
|
Elsaid AA, Elkerm Y. Final results of a randomized phase Ⅲ trial of docetaxel, carboplatin and 5FU versus epiru-bicin, cisplatin and 5FU for locally advanced gastric cancer[J]. J Clin Oncol, 2005, 23: 4014. doi: 10.1200/jco.2005.23.16_suppl.4014 |
[24]
|
Van Cutsem E, Boni C, Tabernero J, et al. Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase Ⅱstudy[J]. Ann Oncol, 2015, 26: 149-156. doi: 10.1093/annonc/mdu496 |
[25]
|
Shah MA, Janjigian YY, Stoller R, et al. Randomized multicenter phase Ⅱ study of modified docetaxel, cisplatin, and fluorouracil(DCF) versus DCF plus growth factor support in patients with metastatic gastric adenocarcinoma: a study of the US Gastric Cancer Consortium[J]. J Clin Oncol, 2015, 33: 3874-3879. doi: 10.1200/JCO.2015.60.7465 |
[26]
|
Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemother-apy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial[J]. Lancet, 2010, 376: 687-697. doi: 10.1016/S0140-6736(10)61121-X |
[27]
|
Chung HC, Bang YJ, Fuchs CS, et al. First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811[J]. Future Oncol, 2021, 17: 491-501. doi: 10.2217/fon-2020-0737 |
[28]
|
Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial[J]. Lancet, 2021, 398: 27-40. doi: 10.1016/S0140-6736(21)00797-2 |
[29]
|
Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial[J]. Lancet, 2014, 383: 31-39. doi: 10.1016/S0140-6736(13)61719-5 |
[30]
|
Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial[J]. Lancet Oncol, 2014, 15: 1224-1235. doi: 10.1016/S1470-2045(14)70420-6 |
[31]
|
Oaknin A, Tinker AV, Gilbert L, et al. Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: a nonrandomized phase 1 clinical trial[J]. JAMA Oncol, 2020, 6: 1766-1772. doi: 10.1001/jamaoncol.2020.4515 |
[32]
|
Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase Ⅱ KEYNOTE-158 study[J]. J Clin Oncol, 2020, 38: 1-10. |